Targeted & controlled bone healing
29 Nov 18
Extraordinary General Meeting of Kuros Biosciences approves all resolutions

MEDIA RELEASE

Extraordinary General Meeting of Kuros Biosciences approves all resolutions

Schlieren (Zurich), Switzerland, November 29, 2018 – Kuros Biosciences (SIX: KURN) (the Company or Kuros) announces that today’s Extraordinary General Meeting (EGM) approved all resolutions proposed by the Board of Directors with a clear majority. A total of 36.3% of shares was represented at the EGM.

 

Shareholder resolved the increase of the ordinary share capital of up to CHF4`301`464 by issuing up to 4`301`464 new ordinary shares with a nominal value of CHF 1.00 each and the creation of a conditional capital for bond s or similar instruments in the amount of CHF 1`720`585 to issue a maximum of 1`720`585 registered shares, each with a nominal value CHF1.00 and the corresponding changes in the Articles of Association.

 

The Extraordinary General Meeting took place at the Company`s headquarters in Schlieren. It was attended by 31 shareholders. 3.124.156 shares or 36.2% of a total 8.606.929 shares were represented.



Kuros Biosciences AG
Wagistrasse 25, 8952 Schlieren, Switzerland
Tel: +41 44 733 47 47   Fax: +41 44 733 47 40   Email: info@kurosbio.com

About Kuros

  1. Overview
  2. Executive Committee
  3. Board
  4. Careers

Products

  1. MagnetOs

Pipeline

  1. Pipeline
  2. Spinal fusion
    KUR-113
  3. Fracture repair
    KUR-111
    KUR-113
  4. Surgical Sealants
    Neuroseal (KUR-023)

Technologies

  1. Surface Science Technology
  2. Fibrin-Based
  3. Synthetic Cross-Linking Technology
  4. Immune Modulation

Partnerships

  1. Collaborations
  2. Business Development

Investors

  1. Share price
  2. Regulatory filings
  3. Reports & Presentations
  4. Analysts
  5. Calendar
  6. Corporate governance
  7. Stay informed

News

  1. Press releases
  2. Conferences & Events

Contact

  1. Location
Article
29 Nov 18
Extraordinary General Meeting of Kuros Biosciences approves all resolutions

MEDIA RELEASE

Extraordinary General Meeting of Kuros Biosciences approves all resolutions

Schlieren (Zurich), Switzerland, November 29, 2018 – Kuros Biosciences (SIX: KURN) (the Company or Kuros) announces that today’s Extraordinary General Meeting (EGM) approved all resolutions proposed by the Board of Directors with a clear majority. A total of 36.3% of shares was represented at the EGM.

 

Shareholder resolved the increase of the ordinary share capital of up to CHF4`301`464 by issuing up to 4`301`464 new ordinary shares with a nominal value of CHF 1.00 each and the creation of a conditional capital for bond s or similar instruments in the amount of CHF 1`720`585 to issue a maximum of 1`720`585 registered shares, each with a nominal value CHF1.00 and the corresponding changes in the Articles of Association.

 

The Extraordinary General Meeting took place at the Company`s headquarters in Schlieren. It was attended by 31 shareholders. 3.124.156 shares or 36.2% of a total 8.606.929 shares were represented.